ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.73 Million GBP | 25.08% |
| 2022 | -8.98 Million GBP | 35.74% |
| 2021 | -13.98 Million GBP | -18.99% |
| 2020 | -11.75 Million GBP | 39.51% |
| 2019 | -19.42 Million GBP | 27.81% |
| 2018 | -26.91 Million GBP | 4.31% |
| 2017 | -28.12 Million GBP | -61.39% |
| 2016 | -17.42 Million GBP | -40.75% |
| 2015 | -12.38 Million GBP | 16.99% |
| 2014 | -14.91 Million GBP | -320.59% |
| 2013 | -3.54 Million GBP | 10.77% |
| 2012 | -3.97 Million GBP | 58.81% |
| 2011 | -9.64 Million GBP | -75.56% |
| 2010 | -5.49 Million GBP | -563.02% |
| 2009 | 1.18 Million GBP | 143.37% |
| 2008 | -2.73 Million GBP | 64.33% |
| 2007 | -7.67 Million GBP | -49.47% |
| 2006 | -5.13 Million GBP | -535.08% |
| 2005 | 1.18 Million GBP | 406.44% |
| 2004 | 233 Thousand GBP | 501.72% |
| 2003 | -58 Thousand GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.88 Million GBP | 27.42% |
| 2024 Q2 | -4.73 Million GBP | 3.19% |
| 2023 Q1 | -9.11 Million GBP | -1.48% |
| 2023 Q2 | -8.96 Million GBP | 1.66% |
| 2023 Q3 | -5.88 Million GBP | 34.38% |
| 2023 FY | -6.73 Million GBP | 25.08% |
| 2023 Q4 | -6.73 Million GBP | -14.39% |
| 2022 Q2 | -10.78 Million GBP | 1.33% |
| 2022 Q3 | -9.13 Million GBP | 15.31% |
| 2022 FY | -8.98 Million GBP | 35.74% |
| 2022 Q1 | -10.92 Million GBP | 21.85% |
| 2022 Q4 | -8.98 Million GBP | 1.6% |
| 2021 Q1 | -9.13 Million GBP | 22.29% |
| 2021 FY | -13.98 Million GBP | -18.99% |
| 2021 Q4 | -13.98 Million GBP | 1.11% |
| 2021 Q3 | -14.14 Million GBP | -57.58% |
| 2021 Q2 | -8.97 Million GBP | 1.74% |
| 2020 Q2 | -17.82 Million GBP | 0.86% |
| 2020 Q1 | -17.97 Million GBP | 7.46% |
| 2020 Q4 | -11.75 Million GBP | 1.39% |
| 2020 FY | -11.75 Million GBP | 39.51% |
| 2020 Q3 | -11.91 Million GBP | 33.13% |
| 2019 FY | -19.42 Million GBP | 27.81% |
| 2019 Q1 | -24.72 Million GBP | 8.14% |
| 2019 Q2 | -24.72 Million GBP | 0.0% |
| 2019 Q3 | -19.56 Million GBP | 20.85% |
| 2019 Q4 | -19.42 Million GBP | 0.72% |
| 2018 Q2 | -21.35 Million GBP | 0.0% |
| 2018 FY | -26.91 Million GBP | 4.31% |
| 2018 Q1 | -21.35 Million GBP | 24.06% |
| 2018 Q4 | -26.91 Million GBP | 3.58% |
| 2018 Q3 | -27.91 Million GBP | -30.68% |
| 2017 FY | -28.12 Million GBP | -61.39% |
| 2017 Q4 | -28.12 Million GBP | 0.0% |
| 2017 Q3 | -28.12 Million GBP | -37.76% |
| 2017 Q2 | -20.41 Million GBP | 0.0% |
| 2017 Q1 | -20.41 Million GBP | -17.17% |
| 2016 Q2 | -22.28 Million GBP | 0.0% |
| 2016 FY | -17.42 Million GBP | -40.75% |
| 2016 Q1 | -22.28 Million GBP | -79.98% |
| 2016 Q3 | -17.42 Million GBP | 21.79% |
| 2016 Q4 | -17.42 Million GBP | 0.01% |
| 2015 FY | -12.38 Million GBP | 16.99% |
| 2015 Q1 | -10.09 Million GBP | 32.29% |
| 2015 Q4 | -12.38 Million GBP | 0.01% |
| 2015 Q3 | -12.38 Million GBP | -22.6% |
| 2015 Q2 | -10.09 Million GBP | 0.0% |
| 2014 Q2 | -23.51 Million GBP | 0.0% |
| 2014 FY | -14.91 Million GBP | -320.59% |
| 2014 Q4 | -14.91 Million GBP | 0.01% |
| 2014 Q3 | -14.91 Million GBP | 36.57% |
| 2014 Q1 | -23.51 Million GBP | -563.14% |
| 2013 Q2 | -6.66 Million GBP | 0.0% |
| 2013 Q3 | -3.54 Million GBP | 46.81% |
| 2013 FY | -3.54 Million GBP | 10.77% |
| 2013 Q4 | -3.54 Million GBP | 0.03% |
| 2012 Q4 | -3.97 Million GBP | 0.0% |
| 2012 Q2 | -6.45 Million GBP | 0.0% |
| 2012 FY | -3.97 Million GBP | 58.81% |
| 2011 Q2 | -3.45 Million GBP | 0.0% |
| 2011 FY | -9.64 Million GBP | -75.56% |
| 2011 Q4 | -9.64 Million GBP | 0.0% |
| 2010 FY | -5.49 Million GBP | -563.02% |
| 2010 Q4 | -5.49 Million GBP | 0.0% |
| 2010 Q2 | -2.11 Million GBP | 0.0% |
| 2009 Q4 | 1.18 Million GBP | 0.0% |
| 2009 Q2 | 37 Thousand GBP | 0.0% |
| 2009 FY | 1.18 Million GBP | 143.37% |
| 2008 Q4 | -2.73 Million GBP | 0.0% |
| 2008 Q2 | -5.71 Million GBP | 0.0% |
| 2008 FY | -2.73 Million GBP | 64.33% |
| 2007 Q4 | -7.67 Million GBP | 0.0% |
| 2007 Q2 | -2.78 Million GBP | 0.0% |
| 2007 FY | -7.67 Million GBP | -49.47% |
| 2006 FY | -5.13 Million GBP | -535.08% |
| 2006 Q2 | -7.4 Million GBP | 0.0% |
| 2006 Q4 | -5.13 Million GBP | 0.0% |
| 2005 Q4 | 1.18 Million GBP | 0.0% |
| 2005 FY | 1.18 Million GBP | 406.44% |
| 2005 Q2 | -65 Thousand GBP | 0.0% |
| 2004 FY | 233 Thousand GBP | 501.72% |
| 2003 FY | -58 Thousand GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.27 Million USD | 133.202% |
| Skye Bioscience, Inc. | -5.72 Million USD | -17.664% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -6.78% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2596.899% |
| Qrons Inc. | 351.42 Thousand USD | 2015.618% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 250.536% |
| CSL Limited | 10.52 Billion USD | 100.064% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 115.732% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 219.185% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1159.879% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 115.499% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -32887.064% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2307.213% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -513793.13% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1181.682% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 33985.337% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 142.708% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 263.476% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1775.256% |
| SQZ Biotechnologies Company | -36.23 Million USD | 81.423% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 400.236% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 826.068% |
| Mesoblast Limited | 55.85 Million USD | 112.052% |
| Marizyme, Inc. | 18.56 Million USD | 136.254% |
| Genus plc | 190.6 Million USD | 103.532% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 401.096% |
| Pharming Group N.V. | 109.8 Million USD | 106.131% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 882.571% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 654.582% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1090.0% |
| ContraFect Corporation | -6.02 Million USD | -11.716% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 5100.037% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 682.641% |
| IMV Inc. | 7.67 Million USD | 187.765% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 222.358% |
| MultiCell Technologies, Inc. | 90.04 USD | 7476777.032% |
| ONE Bio Corp. | 9.04 Million USD | 174.469% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -817.194% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 152.001% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 592.116% |
| Q BioMed Inc. | 4.06 Million USD | 265.812% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 122.033% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 768.045% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1046.3% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 111.119% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 436.702% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 152.567% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1971.508% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4915.313% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 405.725% |
| GB Sciences, Inc. | 1.74 Million USD | 485.277% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -3562.916% |
| HST Global, Inc. | 96.79 Thousand USD | 7055.048% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 3364.522% |
| Halberd Corporation | 144.72 Thousand USD | 4751.709% |
| Enzolytics Inc. | 981.65 Thousand USD | 785.78% |
| Agentix Corp. | 37.63 Thousand USD | 17989.506% |
| Resverlogix Corp. | 6.45 Million USD | 204.356% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -900.165% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.668% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 85.68% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 195.206% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 348.54% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 23.845% |
| AVAX Technologies, Inc. | -5.9 Million USD | -14.04% |
| Zenith Capital Corp. | 10.06 Thousand USD | 66991.892% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.366% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 3458.745% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 382.142% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 4192.177% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -36650.737% |
| Kadimastem Ltd | -253.1 Thousand USD | -2559.797% |
| Helix BioMedix, Inc. | -2.57 Million USD | -161.942% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 3445.027% |
| LadRx Corporation | -2.03 Million USD | -230.572% |
| Cell Source, Inc. | 9.23 Million USD | 172.921% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1159.879% |
| NovAccess Global Inc. | 2.17 Million USD | 409.025% |
| Affymax, Inc. | -5.59 Million USD | -20.279% |
| Itoco Inc. | 228.3 Thousand USD | 3048.687% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 5050.4% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 235.808% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1490.243% |
| CytoDyn Inc. | 20.26 Million USD | 133.225% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1040394.59% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -72534.366% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 187.36% |
| SYBLEU INC | 473.71 Thousand USD | 1521.111% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 251.043% |
| International Stem Cell Corporation | 2.59 Million USD | 359.923% |
| Bioxytran, Inc. | 1.89 Million USD | 454.518% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 10886.214% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 408.68% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 296.04% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 178.709% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 971.336% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -438.56% |
| Neutra Corp. | 52.18 Thousand USD | 12999.764% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -170.47% |
| PureTech Health plc | -167.19 Million USD | 95.974% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2648.787% |
| IXICO plc | -4.44 Million USD | -51.465% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 150.927% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 112.273% |
| CSL Limited | 10.52 Billion USD | 100.064% |
| Cellectis S.A. | -43.81 Million USD | 84.637% |